US › Healthcare

Sana Biotechnology Inc (SANA)

US · Healthcare · Biotechnology

$3.40+6.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-47.2M
Profit YoY
+4.4%
EPS
$-0.14
EPS estimate
$-0.15

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap
$871.1M
Forward P/E
0.0
P/B
7.30
Book value
$0.44
EPS (TTM)
$-0.92
52-week high
$6.55
52-week low
$2.61
50-day MA
$3.26
200-day MA
$3.83
Beta
2.14

Analyst view

Analysts rate Sana Biotechnology Inc a buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $8.57.

Shareholding

Insiders
6.51%
Institutions
82.86%

Largest institutional holders

FundStake
FMR Inc13.45%
Flagship Ventures Management, Inc.8.98%
BlackRock Inc5.12%
State Street Corp3.79%
Canada Pension Plan Investment Board3.67%
Vanguard Capital Management, LLC2.67%
Baillie Gifford & Co Limited.2.37%
Geode Capital Management, LLC1.50%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sana Biotechnology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.